CHELSEA TANG: Open Payments
NPI 1740954387 · SPRINGFIELD, OR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$430 in 20 payments from 10 companies in 2025. Trend: 2023 $515 · 2024 $620 · 2025 $430
Food & beverage: $430
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 5 | $85 |
| ABBVIE INC. | 3 | $77 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $64 |
| Amgen Inc. | 2 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $31 |
| Aimmune Therapeutics, Inc. | 1 | $29 |
| Exact Sciences Corporation | 1 | $28 |
| AstraZeneca Pharmaceuticals LP | 1 | $24 |
| Lilly USA, LLC | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $21 |
Products named: JARDIANCE, REXULTI, MAVYRET, OTEZLA, GEMTESA, ZENPEP, Cologuard Collection Kit, AIRSUPRA.
Industry payments across OR — which companies pay providers there.
